A5084595779- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- DNA Repair Mechanisms
- Lung Cancer Treatments and Mutations
- Cancer Treatment and Pharmacology
- Protein Tyrosine Phosphatases
- RNA modifications and cancer
- 3D Printing in Biomedical Research
- Bone health and treatments
- Pancreatic and Hepatic Oncology Research
- Monoclonal and Polyclonal Antibodies Research
- Cytokine Signaling Pathways and Interactions
- Galectins and Cancer Biology
- Single-cell and spatial transcriptomics
- Oral and Maxillofacial Pathology
- Medical Imaging Techniques and Applications
- Cancer, Hypoxia, and Metabolism
- Cancer Research and Treatments
- HER2/EGFR in Cancer Research
- Microfluidic and Bio-sensing Technologies
- Cell Adhesion Molecules Research
- Radiomics and Machine Learning in Medical Imaging
- Radiopharmaceutical Chemistry and Applications
- Prostate Cancer Treatment and Research
- Molecular Biology Techniques and Applications
ETH Zurich
2021-2027
École Polytechnique Fédérale de Lausanne
2021-2025
The Geneva Association
2023-2024
University of Basel
2014-2022
University Hospital of Basel
2017-2021
Massachusetts General Hospital
2014-2021
Harvard University
2014-2020
Friedrich Miescher Institute
2008-2014
Dana-Farber/Harvard Cancer Center
2014
Novartis (Switzerland)
2013
Circulating tumor cells (CTCs) are present at low concentrations in the peripheral blood of patients with solid tumors. It has been proposed that isolation, ex vivo culture, and characterization CTCs may provide an opportunity to noninvasively monitor changing patterns drug susceptibility individual as their tumors acquire new mutations. In a proof-of-concept study, we established CTC cultures from six estrogen receptor-positive breast cancer. Three five lines tested were tumorigenic mice....
The ability of circulating tumor cells (CTCs) to form clusters has been linked increased metastatic potential. Yet biological features and vulnerabilities CTC remain largely unknown. Here, we profile the DNA methylation landscape single CTCs from breast cancer patients mouse models on a genome-wide scale. We find that binding sites for stemness- proliferation-associated transcription factors are specifically hypomethylated in clusters, including OCT4, NANOG, SOX2, SIN3A, paralleling...
Highlights•Pancreatic CTCs can be enriched with antigen-agnostic microfluidic technology•Single-cell RNA sequencing of pancreatic reveals three distinct CTC populations•Extracellular matrix genes are highly expressed in mouse and human CTCs•The extracellular protein SPARC contributes to tumor metastasisSummaryCirculating cells (CTCs) shed from primary tumors into the bloodstream, mediating hematogenous spread cancer distant organs. To define their composition, we compared genome-wide...
Metastasis: A matter of translation? Solid tumors shed a small number cancer cells into the bloodstream, some which are believed to contribute metastasis. The molecular features that confer these circulating tumor (CTCs) with metastatic potential poorly understood. Ebright et al. studied CTCs from breast patients and found increased expression levels certain ribosomal proteins regulators translation had greater capacity in mouse model (see Perspective by Ma Jeffrey). Consistent this finding,...
Circulating tumor cells (CTCs) are shed from solid cancers in the form of single or clustered cells, and latter display an extraordinary ability to initiate metastasis. Yet, biological phenomena that trigger shedding CTC clusters a primary cancerous lesion poorly understood. Here, when dynamically labeling breast cancer along progression, we observe majority undergoing hypoxia, while CTCs largely normoxic. Strikingly, find vascular endothelial growth factor (VEGF) targeting leads shrinkage,...
Abstract The presence of circulating tumor cell (CTC) clusters is associated with disease progression and reduced survival in a variety cancer types. In breast cancer, preclinical studies showed that inhibitors the Na + /K ATPase suppress CTC block metastasis. Here we conducted prospective, open-label, proof-of-concept study women metastatic where primary objective was to determine whether treatment inhibitor digoxin could reduce mean cluster size. An analysis nine patients treated daily...
A layer-by-layer gelatin nanocoating is presented for use as a tunable, dual response biomaterial the capture and release of circulating tumor cells (CTCs) from cancer patient blood. The entire can be dissolved surface microfluidic devices through biologically compatible temperature shifts. Alternatively, individual CTCs released locally applied mechanical stress.
Both abundant epidermal growth factor receptor (EGFR or ErbB1) and high activity of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway are common therapeutically targeted in triple-negative breast cancer (TNBC). However, activation another EGFR family member [human 3 (HER3) (or ErbB3)] may limit antitumor effects these drugs. We found that TNBC cell lines cultured with HER3 ligand EGF heregulin, respectively, treated either an Akt inhibitor (GDC-0068) a PI3K (GDC-0941) had increased...
Copper chelators could help to reduce metastasis from breast tumors.
Metastases claim more than 90% of cancer-related patient deaths and are usually seeded by a subset circulating tumor cells shed off from the primary tumor. In circulation, found both as single clusters cells. The cells, although many fewer in number, possess much higher metastatic potential compared to that individual this review, we highlight recent insights into molecular mechanisms can enable formation these clusters-(a) hybrid epithelial/mesenchymal phenotype couples their ability...
A new CTC isolation approach uncovers special populations of platelet-coated CTCs and CTC-leukocyte clusters in cancer patients.
TGF-β secreted by tumor stroma induces epithelial-to-mesenchymal transition (EMT) in cancer cells, a reversible phenotype linked to progression and drug resistance. However, exposure stromal signals may also lead heritable changes which are poorly understood. We show that epithelial cells failing undergo proliferation arrest during TGF-β-induced EMT sustain mitotic abnormalities due failed cytokinesis, resulting aneuploidy. This genomic instability is associated with the suppression of...
Human glioblastoma (GBM) is a highly aggressive, invasive and hypervascularised malignant brain cancer. Individual circulating tumour cells (CTCs) are sporadically found in GBM patients, yet it unclear whether multicellular CTC clusters generated this disease they can bypass the physical hurdle of blood-brain barrier. Here, we assessed presence composition at multiple time points 13 patients with progressing during an open-label phase 1/2a study microtubule inhibitor BAL101553. We observe...